Artículos por temáticas

Deep brain stimulation: potential for neuroprotection

McKinnon C, Gros P, Lee DJ, Hamani C, Lozano AM, Kalia LV, Kalia SK.

Ann Clin Transl Neurol. 2018 Nov 8;6(1):174-185. doi: 10.1002/acn3.682. eCollection 2019 Jan.

Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study

Rapp M, Burkart M, Kohlmann T, Bohlken J.

Int J Clin Pharmacol Ther. 2018 Mar;56(3):130-133. doi: 10.5414/CP203103.

Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB)

Wessels AM, Dowsett SA, Sims JR.

J Prev Alzheimers Dis. 2018;5(1):15-20. doi: 10.14283/jpad.2018.2.

Antiepileptic Drug Use and the Risk of Stroke Among Community-Dwelling People With Alzheimer Disease: A Matched Cohort Study

Sarycheva T, Lavikainen P, Taipale H, Tiihonen J, Tanskanen A, Hartikainen S, Tolppanen AM.

J Am Heart Assoc. 2018 Sep 18;7(18):e009742. doi: 10.1161/JAHA.118.009742.

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions

Geifman N, Kennedy RE, Schneider LS, Buchan I, Brinton RD.

Alzheimers Res Ther. 2018 Jan 15;10(1):4. doi: 10.1186/s13195-017-0332-0.

Exercise-induced brain-derived neurotrophic factor expression: Therapeutic implications for Alzheimer's dementia

Wang R, Holsinger RMD.

Ageing Res Rev. 2018 Dec;48:109-121. doi: 10.1016/j.arr.2018.10.002. Epub 2018 Oct 13.

Similar clinical improvement and maintenance after rTMS at 5 Hz using a simple vs. complex protocol in Alzheimer's disease

Alcalá-Lozano R, Morelos-Santana E, Cortés-Sotres JF, Garza-Villarreal EA, Sosa-Ortiz AL, González-Olvera JJ.

Brain Stimul. 2018 May-Jun;11(3):625-627. doi: 10.1016/j.brs.2017.12.011. Epub 2017 Dec 29.

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial

Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ.

Am J Psychiatry. 2018 Feb 1;175(2):159-168. doi: 10.1176/appi.ajp.2017.17030316. Epub 2017 Sep 15.

A comparative study of eicosapentaenoic acid enriched phosphatidylcholine and ethyl ester in improving cognitive deficiency in Alzheimer's disease model rats

Wen M , Ding L , Zhang L , Cong P , Zhang T , Xu J , Chang Y , Wang Y , Xue C .

Food Funct. 2018 Apr 25;9(4):2184-2192. doi: 10.1039/c7fo01815k.

Incontinence in nursing home residents with dementia : Influence of an educational program and nursing case conferences

Kohler M, Schwarz J, Burgstaller M, Saxer S.

Z Gerontol Geriatr. 2018 Jan;51(1):48-53. doi: 10.1007/s00391-016-1120-3. Epub 2016 Sep 6.

Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease

Ritchie CW, Khandker RK, Pike J, Black CM, Jones E, Ambegaonkar BM.

J Alzheimers Dis. 2018;64(3):899-910. doi: 10.3233/JAD-180306.

Comparison of multiple interventions for older adults with Alzheimer disease or mild cognitive impairment: A PRISMA-compliant network meta-analysis

Liang JH, Xu Y, Lin L, Jia RX, Zhang HB, Hang L.

Medicine (Baltimore). 2018 May;97(20):e10744. doi: 10.1097/MD.0000000000010744.

The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing

Blaszczyk AT, Mang BH, Garza H, Mathys M.

Consult Pharm. 2018 May 1;33(5):273-282. doi: 10.4140/TCP.n.2018.273..

Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus

Klimova B, Kuca K, Maresova P.

Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul

Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.